Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Amgen
(NQ:
AMGN
)
320.32
-1.89 (-0.59%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
2,036,948
Open
322.05
Bid (Size)
315.09 (1)
Ask (Size)
322.30 (1)
Prev. Close
322.21
Today's Range
316.92 - 322.20
52wk Range
249.70 - 346.85
Shares Outstanding
N/A
Dividend Yield
2.66%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
(AMGN) - Analyzing Amgen's Short Interest
September 30, 2024
Via
Benzinga
AskSlim Market Week - Friday, Sep. 27
September 27, 2024
An analysis and commentary on the financial markets.
Via
Talk Markets
Performance
YTD
+7.71%
+7.71%
1 Month
-3.08%
-3.08%
3 Month
+2.99%
+2.99%
6 Month
+13.17%
+13.17%
1 Year
+20.28%
+20.28%
More News
Read More
Stock Market Rally Hits Fresh Highs, Fueled By Micron Earnings, China Stimulus: Weekly Review
September 27, 2024
Via
Investor's Business Daily
Topics
Stocks
Exposures
US Equities
Taiwan Semiconductor, American Tower, Trane Technologies And A Health Care Stock On CNBC's 'Final Trades'
September 26, 2024
Via
Benzinga
Analyst Expectations For Amgen's Future
September 25, 2024
Via
Benzinga
Market Whales and Their Recent Bets on AMGN Options
September 24, 2024
Via
Benzinga
What the Options Market Tells Us About Amgen
September 23, 2024
Via
Benzinga
Interesting Technical Analysis finding for AMGEN INC (NASDAQ:AMGN)
September 20, 2024
Via
Chartmill
Amgen's Rocatinlimab Has Commercial Potential Despite Competitive Landscape, Says Goldman Sachs
September 25, 2024
Via
Benzinga
Argenx Stock Surges As Amgen Struggles To Take On 'The King' In Autoimmune Diseases
September 25, 2024
Via
Investor's Business Daily
Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market
September 25, 2024
Via
Benzinga
Why Is Regeneron Pharmaceuticals Stock Trading Lower On Tuesday?
September 24, 2024
Via
Benzinga
2 Weight-Loss Stocks That Could Rocket Higher This Year
September 24, 2024
Via
The Motley Fool
Where Will Amgen Be in 5 Years?
September 20, 2024
Via
The Motley Fool
Behind the Scenes of Amgen's Latest Options Trends
September 19, 2024
Via
Benzinga
Tesla Leads S&P 500 Index, While Biotech Giant Tumbles On Court Ruling
September 23, 2024
Via
Investor's Business Daily
Topics
Stocks
Exposures
US Equities
Regeneron Dives As Amgen Tees Up Its Rival To Moneymaking Machine Eylea
September 23, 2024
Via
Investor's Business Daily
Amgen vs. Viking Therapeutics: What's the Better GLP-1 Stock to Buy?
September 23, 2024
Via
The Motley Fool
Can These 5 Assets Skyrocket Your Portfolio?
September 22, 2024
Via
Talk Markets
Topics
ETFs
Stocks
Exposures
US Equities
10 Health Care Stocks With Whale Alerts In Today's Session
September 18, 2024
Via
Benzinga
The Bull Market Strengthened, Let The Naysayers Say Nay...
September 15, 2024
Via
Talk Markets
Time To Invest And Or Trade In Bio-Tech Stocks?
September 13, 2024
Via
Talk Markets
Topics
ETFs
2 Unstoppable Growth Stocks to Buy Right Now for Less Than $500
September 13, 2024
Via
The Motley Fool
Forget Eli Lilly and Novo Nordisk: This Could Be the Best Weight Loss Stock to Buy Right Now
September 12, 2024
Via
The Motley Fool
UnitedHealth Follows Competitors, Replaces Humira with Lower-Cost Biosimilars
September 11, 2024
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.